SCHEMBL2357955

SCHEMBL2357955

Cc1cccc(NC(=O)c2ccccc2C(=O)c2ccc3nc(NC(=O)O)[nH]c3c2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.63
▸ BRAF P15056 5/20 0.63
▸ ALDH1A1 P00352 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ ABL1 P00519 3/20 0.53
▸ CYP2C9 P11712 3/20 0.53
▸ LMNA P02545 2/20 0.53
▸ HTT P42858 2/20 0.53
▸ CYP1A2 P05177 2/20 0.53
▸ ABCC4 O15439 1/20 0.53
▸ USP2 O75604 1/20 0.53
▸ KDR P35968 1/20 0.53
▸ HIF1A Q16665 1/20 0.53
▸ MAPT P10636 3/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ HPGD P15428 1/20 0.52
▸ XIAP P98170 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20525713 0.91 RAF1 (0.73) RAF1BRAFALDH1A1KMT2AMEN1
SCHEMBL3474868 0.89 RAF1 (0.60) RAF1BRAFALDH1A1KMT2AABL1
SCHEMBL3471881 0.89 RAF1 (0.59) RAF1BRAFALDH1A1KMT2AABL1
SCHEMBL2356348 0.89 RAF1 (0.59) RAF1BRAFALDH1A1KMT2AMEN1
SCHEMBL3475822 0.89 RAF1 (0.59) RAF1BRAFALDH1A1KMT2AMEN1
SCHEMBL3473662 0.89 RAF1 (0.59) RAF1BRAFALDH1A1KMT2AABL1
SCHEMBL1791715 0.89 RAF1 (0.59) RAF1BRAFALDH1A1KMT2AABL1
SCHEMBL1791971 0.89 RAF1 (0.64) RAF1BRAFALDH1A1KMT2AMEN1
SCHEMBL2299280 0.87 RAF1 (0.57) RAF1BRAFALDH1A1KMT2AMEN1
SCHEMBL2297139 0.87 RAF1 (0.57) RAF1BRAFALDH1A1KMT2AABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback